They performed genetic engineering of both primary mammary organoids and in vivo models and identified some well-known tumour suppressor genes such as PTEN, RB1, and NF1 and others such as AXIN1, SMAD3, or PRKAR1A that, when mutated, collaborate with TP53 loss during mammary tumorigenesis. This evidence concerns the gene TP53 and neoplasm.